Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03974685
Recruitment Status : Completed
First Posted : June 5, 2019
Last Update Posted : August 8, 2019
Sponsor:
Collaborators:
Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.
MedAlly Solutions Co., Ltd.
Information provided by (Responsible Party):
RDO Pharm.

Brief Summary:

The study drug 99mTc-3PRGD2 of this study is a new radioactive diagnostic preparation for clinical use as a nuclear medicine molecular probe for tumor SPECT/CT imaging.

After 99mTc-3PRGD2 is injected into the body, it is specifically taken up by integrin receptor-positive tumor tissue, and tumor tissue is developed by SPECT/CT, which can be used for molecular imaging diagnosis and individualized treatment of common tumors.

The primary objectives of this study is to examine the pharmacokinetics the safety of 99mTc-3PRGD2 injection in healthy volunteers, as well as the biodistribution in the human body and to estimate the dose of internal radiation absorbed. This study provides the basis for the design of phase II clinical research programs.


Condition or disease Intervention/treatment Phase
Healthy Drug: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2) Phase 1

Detailed Description:

To a large extent, cancer treatment outcomes depend on the accurate diagnosis and staging of the disease. An important basis for early diagnosis of malignant tumors is medical imaging. Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) are most well-developed nuclear medicine procedures based on the measurement of radiolabeled tracer molecules.

These radiotracers allow biologic processes to be measured and whole body images to be obtained, which will demonstrate exact locations of radiotracer accumulation. Functional imagings of SPECT and PET provide specific information which is not available from standard medical imaging modalities such as ultrasound, X-ray, computerized tomography (CT) or magnetic resonance imaging (MRI).

The test drug in this study is a new radioactive diagnostic preparation, consisting of radiochemical (Sodium Pertecheetate [99mTc] Injection) and a kit (including Three core ligands, HYNIC-3PRGD2, Tricine, TPPTS). Before administration, 99mTc:HYNIC-3PRGD2:Tricine:TPPTS (1:1:1:1) chelate compound (99mTc-3PRGD2) will be prepared as per standard opration presedure, which will be used as a molecular probe for SPECT/CT imaging.

The core ligand HYNIC-3PRGD2 is a novel RGD dimer that specifically binds to the integrin αvβ3 receptor with high selectivity and affinity. Integrin αvβ3 is highly expressed in tumor neovascularization. After injection, 99mTc-3PRGD2 will be specifically taken up by the integrin receptor-positive tumor tissue, then be imaged by SPECT/CT. The product can be used for molecular imaging diagnosis and individualized treatment for common tumors such as lung cancer and breast cancer are performed.

The primary objectives of this study is to examine the pharmacokinetics the safety of 99mTc-3PRGD2 injection in healthy volunteers, as well as the biodistribution in the human body and to estimate the dose of internal radiation absorbed. This study provides the basis for the design of phase II clinical research programs.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single Group Assignment drug:0.3mCi/kg
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase I Open Label Trial of Pharmacokinetics and Safety of 99mTc Niacinamide Polyethylene Glycol Bicyclic RGD Peptide (99mTc-3PRGD2) Injection in Healthy Volunteers
Actual Study Start Date : December 12, 2018
Actual Primary Completion Date : January 18, 2019
Actual Study Completion Date : January 18, 2019


Arm Intervention/treatment
Experimental: 99mTc-3PRGD2
Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name:99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
Drug: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
Single dose




Primary Outcome Measures :
  1. AUC(0-t) [ Time Frame: Day 1(dosing day )and Pre-dose,1,2,3,19,33,53,91,120,245 minutes post dose ]
    Area under the Activity-time curve from Hour 0 to the last measurable activity

  2. The %ID(The radioactivity of the urine at each time period/ the total injection activity) [ Time Frame: Day 1(dosing day)and Pre-dose,0-50 minutes,50-120 minutes,2-4 hours, 4-8 hours,8-12 hours,12-24hours post dose ]
    The %ID(The radioactivity of the urine at each time period/ the total injection activity) is calculated

  3. The %ID(The radioactivity of the main organs at each time period/ the total injection activity) [ Time Frame: post-intervention at 4 months ]
    The %ID(The radioactivity of the main organs at each time period/ the total injection activity) is calculated.

  4. The radiation dosimetry of the test drug in organs [ Time Frame: post-intervention at 4 months ]
    The internal radiation dosimetry (Dt,mSv) of each irradiated organ is calculated.

  5. Radiochemical purity [ Time Frame: During procedure ]
    To reflects the stability of the drug in the human body,that Radiochemical purity in urine and blood samples is measured.


Secondary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: 3 days ]
    Assessment of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers;
  • 25 to 45 years of age, male to female ratio 1:1;
  • Body mass index (BMI) ranges from 19 to 25 kg/m2 [Body mass index = body weight (kg)/ height squared (m2)];
  • Clinical laboratory test results are normal, or laboratory values out of normal range is judged as not relevant for the clinical trial by the investigator;
  • Subjects should read, sign an Informed Consent Form and willing to complete the trial according to the regulations.

Exclusion Criteria:

  • Women who are breastfeeding or pregnant;
  • Subjects with primary lesion in important organs;
  • Subjects with mental or physical disorders;
  • History of alcohol abuse or drug abuse;
  • Subjects addict to coffee or smoker;
  • Positive result on tests for HIV antibody, HbsAg or anti-hepatitis C virus antibody;
  • History of allergic reactions to two or more kinds of drugs or foods or allergic to any components of test drug;
  • Subjects with diseases (such as insomnia) are receiving other preventive/therapeutic drugs prior to study administration;
  • Other reasons which, in the opinion of the investigator, would prevent the subject from participating in the study;
  • Any anticipation in other clinical trial within 3 months;
  • Subject received isotope treatment or examination before screening, or received X-ray examination more than three times within one year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03974685


Locations
Layout table for location information
China
Peking Union Medical College Hospital
Beijing, China
Sponsors and Collaborators
RDO Pharm.
Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.
MedAlly Solutions Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Zhaohui Zhu, professor Peking Union Medical College Hospital

Layout table for additonal information
Responsible Party: RDO Pharm.
ClinicalTrials.gov Identifier: NCT03974685     History of Changes
Other Study ID Numbers: FSRDA201801
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by RDO Pharm.:
99mTc-3PRGD2
Integrin ανβ3
Dosimetry

Additional relevant MeSH terms:
Layout table for MeSH terms
Niacinamide
Niacin
Nicotinic Acids
Arginyl-glycyl-aspartic acid
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents
Antineoplastic Agents